2022 Reports
Interim Report Q2
To be released 2022-08-26
Interim Report Q3
To be released 2022-10-21
Year End Report 2022
To be released February 2023
Annual Report 2022
To be released in the spring 2023
Interim Report Q2
To be released 2022-08-26
Interim Report Q3
To be released 2022-10-21
Year End Report 2022
To be released February 2023
Annual Report 2022
To be released in the spring 2023
I-Tech AB is a public held bio-technology company based in Mölndal, Sweden that owns all IP and regulatory rights to the antifouling agent Selektope® (generic name, medetomidine). I-Tech also controls the largest and most efficient source of medetomidine production.
Visit selektope.com
info@i-tech.se
+46 10 30 33 999
I-Tech AB
c/o Astra Zeneca AB
Pepparedsleden 1
SE-431 83 Mölndal
Sweden
